Found 58 articles
Black Diamond Therapeutics, Inc. provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535.
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade GliomaStudy tests targeted agent, BDTX-1535, an EGFR inhibitor with brain-penetrant properties
The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery MethodInnovative technique aims to bypass the most difficult barrier in brain cancer treatment
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI.
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade GliomaResults to be presented at 2023 ASCO Annual Meeting
The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is reporting initial results to the American Society of Clinical Oncology (ASCO) for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma, respectively.
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical OfficerLeading Neuro-Oncologist Yoshie Umemura, MD, Joins Barrow Neurological Institute
The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute.
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
ZentalisTM Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announces preclinical data that supports CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib, the Company’s potentially first-in-class Wee1 inhibitor product candidate.
SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma
SonALAsense today announced that the first cohort in SDT-202 was fully enrolled. SDT-202 is an open-label, dose-escalation trial of SDT in recurrent glioblastoma (rGBM).
The Lung Cancer Research Foundation and the EGFR Resisters, in their second year of a research award partnership, announce the 2022 grant recipients.
Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Brain Tumor Center, is a recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care.
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly pediatric brain cancer with a 2% five-year survival rate.
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0 clinical trial of pamiparib in newly-diagnosed and recurrent glioblastoma in combination with radiation therapy.
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized CareInnovative procedure offers doctors a scientific snapshot of tumor’s genetic evolution during experimental therapy
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.
SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer
Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board
Vivacitas Oncology, Inc. is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier Neuro-Oncology Advisory Board.
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced the opening of a new Phase 0/1b clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant (ATM) kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.
11/8/2021The first week of November was marked by numerous clinical trial announcements. Here’s a look.